Lenvatinib shows positive results vs sorafenib in unresectable hepatocellular carcinoma

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

Despite major advances in immunotherapy, most patients with hepatocellular carcinoma fail to respond to current immune checkpoint inhibitors.

May 15, 2026

Vol.52 No.19

By Dan G. Duda

Cancer Policy

CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, or ACIP, voted in December to rescind its recommendation that all newborns receive a hepatitis B virus vaccine dose within 24 hours of birth.

May 01, 2026

Vol.52 No.17

By Claire Marie Porter

Clinical Roundup

Additional radiation for liver cancer doesn’t increase toxicity, University of Cincinnati study finds

New research from a University of Cincinnati Cancer Center study found external beam radiation therapy is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.

March 13, 2026

Vol.52 No.10

In Brief

UTSW receives SPORE grant from NCI to study liver cancer

The Liver Tumor Program at UT Southwestern Medical Center’s Harold C. Simmons Comprehensive Cancer Center has been selected by NCI as a Specialized Program of Research Excellence.

September 19, 2025

Vol.51 No.34

Clinical Roundup

UCLA study identifies key protein that helps liver cancer resist heat-based treatment

Galectin-1, a sugar-binding protein, plays a critical role in helping hepatocellular carcinoma resist thermal ablation and even thrive after being treated with high heat, according to a study from investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 11, 2025

Vol.51 No.27

In Brief

Yuman Fong delivers the Royal College of Surgeons of Edinburgh Lister Legacy Lecture

Yuman Fong, chair of the Department of Surgery at City of Hope, delivered the Lister Legacy Lecture at the triennial conference of The Royal College of Surgeons of Edinburgh. This presentation honors the long-term impact of Baron Joseph Lister, who brought antiseptic techniques to the practice of surgery.

June 27, 2025

Vol.51 No.25

Lenvatinib shows positive results vs sorafenib in unresectable hepatocellular carcinoma

YOU MAY BE INTERESTED IN

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show

Additional radiation for liver cancer doesn’t increase toxicity, University of Cincinnati study finds

UTSW receives SPORE grant from NCI to study liver cancer

UCLA study identifies key protein that helps liver cancer resist heat-based treatment

Yuman Fong delivers the Royal College of Surgeons of Edinburgh Lister Legacy Lecture

Renew today!

Subscriber content

Never miss an issue!

Login